Effect and Safety of Pioglitazone-Metformin Tablets in the Treatment of Newly Diagnosed Type 2 Diabetes Patients with Nonalcoholic Fatty Liver Disease in Shaanxi Province: A Randomized, Double-Blinded, Double-Simulated Multicenter Study
Table 1
Baseline characteristics of study population.
Metformin + pioglitazone ()
Metformin ()
Demographics
Age
57.63 (13.44)
61.25 (11.93)
0.8351
Gender
Male
41 (68.33)
45 (75.00)
0.4178
Female
19 (31.67)
15 (25.00)
Physical examination
SBP (mmHg)
0.1239
DBP (mmHg)
0.1087
Height (cm)
0.5561
Weight (cm)
0.3980
BMI (kg/m2)
0.5479
Waist (cm)
0.1046
Hipline (cm)
0.6325
Waist-to-hip ratio
0.0491
Smoking history
No smoking
40 (67.80)
41 (69.49)
0.8071
Occasional smoking
4 (6.78)
2 (3.39)
Regular smoker
15 (25.42)
16 (27.12)
Diabetes control
Diet therapy
No
22 (37.93)
28 (47.46)
0.2977
Yes
36 (62.07)
31 (52.54)
Exercise therapy
No
22 (37.93)
28 (47.46)
0.2977
Yes
36 (62.07)
31 (52.54)
Nonalcoholic fatty liver control
Diet therapy
No
26 (47.27)
30 (50.85)
0.7572
Yes
29 (52.73)
29 (49.15)
Exercise therapy
No
30 (54.55)
31 (53.45)
0.9470
Yes
25 (45.45)
27 (46.55)
Drug therapy
No
51 (92.73)
50 (84.75)
0.6798
Yes
4 (7.27)
9 (15.25)
Abbreviations: SBP: systolic blood pressure; DBP: diastolic blood pressure. Data are (%) or mean (SD) .
